¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"active fructose"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active negativism
    Àû±Ø°ÅºÎÁõ
  • active oxygen
    Ȱµ¿»ê¼Ò, Ȱ¼º»ê¼Ò
  • active phase
    Ȱ¼º±â
  • active placebo
    Ȱ¼º¼ÓÀÓ¾à
  • active prosthesis
    Ȱµ¿ÀÇÁö, ´Éµ¿ÀÇÁö
  • active shielding
    ´Éµ¿Â÷Æó
  • active shimming
    ´Éµ¿º¸Á¤
  • active site
    Ȱ¼ººÎÀ§
  • active transport
    ´Éµ¿¿î¹Ý
  • active treatment
    Àû±ØÄ¡·á
  • active tuberculosis
    Ȱµ¿°áÇÙ
  • chronic active hepatitis
    ¸¸¼ºÈ°µ¿°£¿°
  • chronic active photosensitive dermatitis
    ¸¸¼ºÈ°¼º±¤¼±°ú¹ÎÇǺο°
  • MR active nuclei
    ÀÚ±â°ø¸íȰ¼ºÇÙ
  • surface-active disinfectant
    Ç¥¸éȰ¼º¼Òµ¶Á¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active placebo
    ¾ç¼º¼ÓÀÓ¾à
  • active prosthesis
    Ȱµ¿ÀÇÁö, ´Éµ¿ÀÇÁö
  • active shielding
    ´Éµ¿°¡¸², ´Éµ¿Â÷Æó
  • active shimming
    ´Éµ¿º¸Á¤
  • active site
    Ȱ¼ººÎÀ§
  • active transport
    ´Éµ¿¿î¹Ý
  • active treatment
    Àû±ØÄ¡·á
  • active tuberculosis
    Ȱµ¿°áÇÙ
  • active gradient shielding
    ´Éµ¿±â¿ï±âÂ÷Æó, ´Éµ¿°æ»çÂ÷Æó
  • active incorporative mode
    Àû±ØÇÔÀÔ¾ç½Ä
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª
  • chronic active photosensitive dermatitis
    ¸¸¼ºÈ°¼º±¤¼±°ú¹ÎÇǺο°
  • chronic active hepatitis
    ¸¸¼ºÈ°µ¿°£¿°
  • surface-active disinfectant
    Ç¥¸éȰ¼º¼Òµ¶Á¦, °è¸éȰ¼º¼Òµ¶Á¦
  • metabolically active stone
    ´ë»çȰ¼ºµ¹
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active apperception
    ÀÚµ¿(Àû)Åë°¢(ÀÛ¿ë)(í»ÔÑîÜ÷ÖÊÆíÂéÄ).
  • active carbon
    Ȱ¼ºÅº(üÀàõ÷©).
  • active earth
    Ȱ¼ºÅä(Ì·ËÛ̬).
  • active exercise
    ÀÚµ¿¿îµ¿(í»ÔÑê¡ÔÑ).
  • active exercise
    ÀÚµ¿¿îµ¿(í»ÔÑê¡ÔÑ).
  • active force generation test
    ±Ù·Â°Ë»ç
  • active glycine
    Ȱ¼º(üÀàõ)±Û¸®½Å.
  • active gradient shielding
    ´Éµ¿ °æ»ç Â÷Æó
  • active hydrogen
    Ȱ¼º¼ö¼Ò(¡­â©áÈ).
  • active imagination
    Àû±ØÀû »ó»ó
  • active immunity
    ´Éµ¿¸é¿ª(ÒöÔÑØóæ¹).
  • active immunization
    ´Éµ¿¸é¿ª(È­)(ÊÙÌ´).
  • active immunization
    ´Éµ¿¸é¿ª¹ý, ´Éµ¿¸é¿ªÁ¶Ä¡
  • active incorporative mode
    Àû±ØÀû ÇÔÀÔ ¾ç½Ä
  • active marrow
    Àû°ñ¼ö.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active carbon
    Ȱ¼ºÅº(üÀàõ÷©).
  • active earth
    Ȱ¼ºÅä(Ì·ËÛ̬).
  • active exercise
    ÀÚµ¿¿îµ¿(í»ÔÑê¡ÔÑ).
  • active exercise
    ÀÚµ¿¿îµ¿(í»ÔÑê¡ÔÑ).
  • active force generation test
    ±Ù·Â°Ë»ç
  • active glycine
    Ȱ¼º(üÀàõ)±Û¸®½Å.
  • active gradient shielding
    ´Éµ¿ °æ»ç Â÷Æó
  • active hydrogen
    Ȱ¼º¼ö¼Ò(¡­â©áÈ).
  • active imagination
    Àû±ØÀû »ó»ó
  • active immunity
    ´Éµ¿¸é¿ª(ÒöÔÑØóæ¹).
  • active immunization
    ´Éµ¿¸é¿ª¹ý, ´Éµ¿¸é¿ªÁ¶Ä¡
  • active immunization
    ´Éµ¿¸é¿ª(È­)(ÊÙÌ´).
  • active incorporative mode
    Àû±ØÀû ÇÔÀÔ ¾ç½Ä
  • active marrow
    Àû°ñ¼ö.
  • active material
    Ȱ¼º¹°Áú(üÀàõÚªòõ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active carbon
    Ȱ¼ºÅº (üÀàõ÷©)
  • active carbon dioxide
    Ȱ¼ºÀÌ»êȭź¼Ò (üÀàõì£ß«ûù÷©áÈ)
  • active center
    Ȱ¼ºÁß½É(üÀàõñéãý)
  • active concentration
    Ȱ¼º³óµµ(üÀàõÒØÓø)
  • active form
    Ȱ¼ºÇü(üÀàõû¡)
  • active formaldehyde
    Ȱ¼º(üÀàõ)Æ÷¸§¾Ëµ¥ÇÏÀ̵å
  • active formate
    Ȱ¼º(üÀàõ)Æ÷¸§»ê(ß«)
  • active formimino
    Ȱ¼º(üÀàõ) Æ÷¸§À̹̳ë
  • active glycolaldehyde
    Ȱ¼º(üÀàõ)±Û¸®Äݾ˵¥ÇÏÀ̵å
  • active hydroxyethyl
    Ȱ¼º(üÀàõ)ÇÏÀ̵å·Ï½Ã¿¡Æ¿
  • active hydroxymethyl
    Ȱ¼º(üÀàõ)ÇÏÀ̵å·Ï½Ã¸ÞÆ¿
  • active immunity
    ´Éµ¿¸é¿ª(ÒöÔÑØóæ¹)
  • active iodine
    Ȱ¼º(üÀàõ)¿äµå
  • active mediated transport
    ´Éµ¿¸Å°³¼ö¼Û (ÒöÔÑØÚË¿âÃáê)
  • active methionine
    Ȱ¼º(üÀàõ)¸ÞŸÀÌ¿À´Ñ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
FDP fibrin degradation product; fibrinogen degradation product; flexor digitorum profundus; frontodextra...
FDPase fructose-1,6-diphosphatase
FMP faculty mentorship program; first menstrual period; fructose monophosphate
F1P, F-1-P fructose-1-phosphate
F6P, F-6-P fructose-6-phosphate
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
FBP Fructose 1,6-biphosphate
FBPase fructose-1,6-biophosphatases
FDPase Fructose-1,6-diphosphatase
F-1-P Fructose-1-phosphate
GFOR Glucose-fructose oxidoreductase
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • active sensitization
    ´Éµ¿ °¨ÀÛ, ´Éµ¿Àû °¨ÀÛ
    »ýü¿¡ Ç׿øÀ» ÁÖ»çÇÑ °á°ú ³ªÅ¸³ª´Â ¿¹¹Î¼º.
  • active shimming
    ´Éµ¿ º¸Á¤
  • active state
    Ȱµ¿ »óÅÂ
    ±ÙÀ°ÀÌ ¼öÃàÇÒ ¶§, ¼öÃà¿ä¼Ò ÀÚü¿¡ ÀϾ°í ÀÖ´Â ¿ªÇÐÀû »óÅÂÀÌ´Ù. ±ÙÀ° ÀÚü¿¡ ź¼º¿ä¼Ò°¡ Á¸ÀçÇϹǷΠ´Ü¼øÇÑ ¼öÃà°î¼±ÀÇ ±â·ÏÀ¸·Î Ȱµ¿»óȲÀ» ¾Ë ¼ö ¾ø´Ù. ¼öÃà¿ä¼Ò´Â ±ÙÀ°ÀÌ ÀڱصǸé Áï½Ã Ȱµ¿»óŰ¡ µÇ°í, Á¦2, Á¦3ÀÇ ÀÚ±ØÀÌ °¡ÇØÁ®µµ ÀÌ È°µ¿»óÅ´ °­È­µÇÁö ¾Ê°í ´Ü¼øÈ÷ Áö¼Ó½Ã°£ÀÌ ¿¬ÀåµÉ »ÓÀÌ´Ù.
  • active transport
    ´Éµ¿ À̵¿
    È®»ê¿¡ ÀÇÇØ¼­°¡ ¾Æ´Ï¶ó ¿î¹Ýü¿¡ ÀÇÇØ ¿¡³ÊÁö¸¦ ¼ÒºñÇØ °¡¸ç ³óµµ¿¡ ¿ªÇàÇØ¼­ ¹°ÁúÀÌ À̵¿µÇ´Â Çö»ó.
  • active tuberculosis
    Ȱµ¿¼º °áÇÙ, Ȱµ¿¼º °áÇÙÁõ
    ȯÀÚ¿¡¼­ ±ÕÀÌ °ËÃâµÇ´Â »óÅ¿¡ ÀÖ´Â °áÇÙ.
  • chronic active hepatitis
    ¸¸¼º Ȱµ¿¼º °£¿°
  • coagualtion-active substance
    ÀÀ°í Ȱ¼º ¹°Áú
  • full active opening
    ´Éµ¿ °³±¸·®
  • multiple biologically active peptide fragment
    ´Ù¹ß¼º »ý¹°ÇÐÀû Ȱ¼º ÆéŸÀÌµå ºÐÀý
  • natural active immunity
    ÀÚ¿¬ ´Éµ¿ ¸é¿ª
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
fructose-2,6-bisphosphate 6-phosphatase <enzyme> Do not confuse with fructose-2,6-bisphosphate 2-phosphatase (EC 3.1.3.46)
Registry number: EC 3.1.3.54
Synonym: fdp 6-phosphatase, fru(2,6)p2 6-phosphatase
(26 Jun 1999)
fructose 6-phosphate <biochemistry> A phosphorylated six-carbon sugar formed in the second step of glycolysis by the action of phosphoglucose isomerase on glucose-6-phosphate. In the third step, fructose 6-phospate and ATP are used to create fructose 1,6-biphosphate, ADP and a free hydrogen with the aid of phosphofructokinase.
(08 Mar 2000)
fructose-6-phosphate phosphoketolase <enzyme> Catalyses the conversion of d-fructose 6-phosphate and orthophosphate to acetylphosphate and d-erythrose 4-phosphate and water
Registry number: EC 4.1.2.22
Synonym: f6p phosphoketolase
(26 Jun 1999)
fructose-bisphosphatase <enzyme> An enzyme that catalyses the conversion of d-fructose 1,6-bisphosphate and water to d-fructose 6-phosphate and orthophosphate.
Chemical name: D-Fructose-1,6-bisphosphate 1-phosphohydrolase
Registry number: EC 3.1.3.11
(12 Dec 1998)
fructose-bisphosphate aldolase <enzyme> An enzyme of the lyase class that catalyses the cleavage of fructose 1,6-biphosphate to form dihydroxyacetone phosphate and glyceraldehyde 3-phosphate. The enzyme also acts on (3s,4r)-ketose 1-phosphates. The yeast and bacterial enzymes are zinc proteins. (enzyme nomenclature, 1992) e.c. 4.1.2.13.
Chemical name: D-Fructose-1,6-biphosphate D-glyceraldehyde-3-phosphate-lyase
Registry number: EC 4.1.2.13
(12 Dec 1998)
fructose-diphosphate aldolase <enzyme> An enzyme of the lyase class that catalyses the cleavage of fructose 1,6-biphosphate to form dihydroxyacetone phosphate and glyceraldehyde 3-phosphate. The enzyme also acts on (3s,4r)-ketose 1-phosphates. The yeast and bacterial enzymes are zinc proteins. (enzyme nomenclature, 1992) e.c. 4.1.2.13.
Chemical name: D-Fructose-1,6-biphosphate D-glyceraldehyde-3-phosphate-lyase
Registry number: EC 4.1.2.13
(12 Dec 1998)
fructose intolerance An autosomal recessive fructose metabolism disorder due to deficient fructose-1-phosphate aldolase (ec 2.1.2.13) activity, resulting in accumulation of fructose-1-phosphate. The accumulated fructose-1-phosphate inhibits glycogenolysis and gluconeogenesis, causing severe hypoglycaemia following ingestion of fructose. Prolonged fructose ingestion in infants leads ultimately to hepatic failure and death. Patients develop a strong distaste for sweet food, and avoid a chronic course of the disease by remaining on a fructose- and sucrose-free diet.
(12 Dec 1998)
fructose metabolism, inborn errors Inherited abnormalities of fructose metabolism, which include three known autosomal recessive types: hepatic fructokinase deficiency (essential fructosuria), hereditary fructose intolerance, and hereditary fructose-1,6-diphosphatase deficiency. Essential fructosuria is a benign asymptomatic metabolic disorder caused by deficiency in fructokinase, leading to decreased conversion of fructose to fructose-1-phosphate and alimentary hyperfructosaemia, but with no clinical dysfunction; may produce a false-positive diabetes test.
(12 Dec 1998)
fructose permease <chemical> Fructose-specific enzyme II of phosphoenolpyruvate-dependent phosphotransferase system in e. Coli
(26 Jun 1999)
active Characterised by action, not passive, not expectant.
(18 Nov 1997)
active acetate <enzyme> Condensation product of coenzyme A and acetic acid, symbolised as CoAS~COCH3; intermediate in transfer of two-carbon fragment, notably in its entrance into the tricarboxylic acid cycle and in fatty acid synthesis.
This coenzyme plays a huge role in intermediary metabolism, in which cells synthesise, break down or use nutrient molecules for energy production, growth, etc.
Acetyl-coenzyme A synthase is found in bacteria and plants and catalyses the reaction in which acetate enters metabolic pathways and forms acetyl-coenzyme A.
Synonym: acetyl-coenzyme A, active acetate.
(05 Mar 2000)
active aldehyde Any aldehyde derivative of thiamin pyrophosphate.
(05 Mar 2000)
active anaphylaxis Reaction following inoculation of antigen in a subject previously sensitised to the specific antigen, in contrast to passive anaphylaxis.
(05 Mar 2000)
active biomass <cell biology> The amount of a given culture that is actively growing.
(06 May 1997)
active carbon dioxide Activated carbon dioxide, a complex of N-carboxybiotin (biotin + CO2) and an enzyme; the form in which carbon dioxide is added to other molecules in carboxylations; e.g., to methylcrotonyl-CoA to form beta-methylglutaconyl in the catabolism of leucine, and to acetyl-CoA to form malonyl-CoA.
See: acetyl-CoA carboxylase.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á